Relapsed or Refractory DLBCL
1 clinical trials · Condition
◉ Watch Relapsed or Refractory DLBCL
| Record | Firm | Date |
|---|---|---|
| Anti-PD-1 Antibody Plus Chidamide and Rituximab Regimen in Relapsed or Refractory DLBCL (PCR) (NCT05115409) | Sun Yat-sen University | 2022-06-01 |
Track Relapsed or Refractory DLBCL automatically
Every clearance here is in the API, with alerts when new ones post.